The board of directors of Franklin Lakes-based, global medical technology company BD, has unanimously authorized BD management ...

Becton Dickinson & Co. said it’s planning to separate part of its life sciences segment in a move aimed at raising the medical technology company’s stock.

Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest ...

BDX's overall topline in the first quarter of fiscal 2025 continues to benefit from revenue growth in all segments.

Q1 2025 Management View Tom Polen emphasized several key updates, including the planned separation of BD’s Biosciences and Diagnostic Solutions businesses, which aims to create two strategically ...

Becton, Dickinson and Company (NYSE:BDX) authorized to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences business.

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

In keeping with the trend in med tech to return to basics, Becton, Dickinson and Co. plans to split off its biosciences and diagnostic solutions unit to create two pure-play companies. The ‘New BD’ or ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology firm, has announced that its board of directors ...